2023 Help me understand this report
Pb2041: Comparison of Eltrombopag and Avatrombopag in the Treatment of Refractory/Relapsed Aplastic Anemia, a Single Center Study in China
Abstract: Background:Eltrombopag (EPAG), one of the thrombopoietin receptor agonists (TPO-RAs), has been approved for refractory/relapsed aplastic anemia (AA), however, data on avatrombopag (AVA), another TPO-RA are limited, let alone the comparison between the two TPO-RAs.
This publication either has no citations yet, or we are still processing them
Set email alert for when this publication receives citations?
See others like this or search for similar articles
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
